Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
actinic, adjunct, adjunctive, Adrenaclick, adult, advisory, Alabama, allegedly, allergic, amid, analgesic, Andrx, anesthetic, anniversary, anthelmintic, API, Apo, arose, Atlantic, atrial, Aubagio, Aventisub, Boothe, Breath, Buchi, Carpinelli, carryback, Castillo, Chalfont, chronic, clarification, clarify, confined, contractility, contrast, coupon, declaratory, deficit, degradation, depositor, Diamond, diet, disorder, disproportionate, divestiture, dropped, dyslipidemia, Edward, Ehf, elevated, Elizabeth, epinephrine, ethical, excessive, factually, faith, faithfully, family, Fax, feasibility, fibrillation, Fredrickson, Genzyme, heart, Holdco, hyperactivity, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, IIa, implied, incurrence, infection, injector, insignificant, Ireland, irrespective, iteration, ix, joined, Junk, juvenile, Kevin, kidney, Kinney, KPH, Lanoxin, leave, maximize, maximizing, McCrary, Mebedanzole, metaxalone, methylphenidate, mid, mild, minimal, Minnesota, misapplication, misunderstanding, MN, moot, musculoskeletal, myocardial, nationwide, Nina, opioid, opposed, optimizing, outlined, outweigh, overcome, overdue, PBM, peer, pilot, Pipe, pre, PREA, predominance, prepayment, principle, PTC, Pulmicort, put, reacquired, reacquisition, reentered, reevaluate, refinance, regular, repaid, repurpose, rest, resumption, Rugby, safeguarding, Sanofi, script, securitization, sequence, serum, Sevelamar, simplification, Skelaxin, South, specialist, stable, strictly, stringent, Teriflunomide, territory, therapy, TN, tolled, toxicity, training, Tulsa, UFCW, unaccreted, underway, Valerie, Velardi, ventricular, verifiable, verified, vii, viii, Virginia, virtue, Washington, Watson, weighed, West
Removed:
adapt, aggregating, alleged, appeal, Astepro, avoid, backed, Bendroflumethiazide, Britain, carried, Chloroquine, citing, Clara, CodificationTM, Colestipol, Curacao, curtailment, derivatively, drawn, enrichment, epilepsy, excluding, failed, Fargo, fiduciary, Fleming, GDFUA, generating, genericized, grew, havealso, Haverhill, Hsu, imposing, insured, judge, Larry, launching, Leg, liberal, medication, Methyltestosterone, misleading, Mulligan, Nadolol, Nigel, nomenclature, noncompetitive, Opana®ER, Overview, PD, placebo, planned, postherpetic, professional, promulgation, Pyridostigmine, reinstated, resolve, retroactively, RLS, roll, ruled, Santa, Singh, sought, spend, statistical, streamline, Syndrome, Taxpayer, top, Trilipix, unjust, unprofitable, Virender
Filing tables
Filing exhibits
- 10-K Annual report
- 3.2.1 Exhibit 3.2.1
- 3.2.2 Exhibit 3.2.2
- 3.2.3 Exhibit 3.2.3
- 3.2.4 Exhibit 3.2.4
- 3.2.5 Exhibit 3.2.5
- 3.2.6 Exhibit 3.2.6
- 3.2.7 Exhibit 3.2.7
- 3.2.8 Exhibit 3.2.8
- 10.19 Exhibit 10.19
- 10.20.2 Exhibit 10.20.2
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
- 32.2 Exhibit 32.2
- Download Excel data file
- View Excel data file
Related press release
IPXL similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Impax Laboratories, Inc.:
We consent to the incorporation by reference in the Registration Statements (Nos. 333-158259, 333-168584, 333-189360, and 333-213677) on Form S-8 of Impax Laboratories, Inc. of our report dated March 1, 2017, with respect to the consolidated balance sheets of Impax Laboratories, Inc. as of December 31, 2016 and 2015, and the related consolidated statements of operations, comprehensive (loss) income, changes in stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2016, and the related financial statement schedule, and the effectiveness of internal control over financial reporting as of December 31, 2016, which reports appear in the December 31, 2016 annual report on Form 10-K of Impax Laboratories, Inc.
/s/ KPMG LLP
Philadelphia, Pennsylvania
March 1, 2017